GM 1077Alternative Names: Astenose
Latest Information Update: 15 Mar 1995
At a glance
- Originator Glycomed
- Class Antihyperlipidaemics; Antithrombotics; Glycosaminoglycans; Vascular disorder therapies
- Mechanism of Action Glycosylation stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Atherosclerosis; Coronary artery restenosis; Thrombosis
Most Recent Events
- 15 Mar 1995 Discontinued-Preclinical for Atherosclerosis in USA (Unknown route)